Beyond Visibility: Redefining the Future of Pharma Supply Chains
From a survey of over 300 decision-makers across the global pharmaceutical sector, the results contained in this report show an industry at a crossroads. A growing market for biologics, gene therapies, and other temperature-sensitive products demands increasingly strict controls and traceability, and reducing cold chain failures is a widely-shared priority among respondents.
In addition, the report finds that companies are navigating new regulatory demands, persistent cold chain vulnerabilities, and rising product complexity—but that many still lack the end-to-end visibility required to manage these challenges effectively.
These findings underscore the urgent need for IoT-enabled visibility tools, risk management platforms, and end-to-end data integration—critical to ensuring patient safety, protecting product integrity, and reducing costly disruptions.
This valuable research is provided for your complimentary access by Tive—download your copy today!
Get your copy
Key Findings:
- Regulatory compliance remains the top priority. Good Distribution Practice (GDP) and evolving mandates, especially in Europe, were cited as the most pressing supply chain challenges.
- Data quality remains a weak spot. Lack of real-time data, difficulties digitizing and sharing it across systems, and trust in received data were among the top challenges reported.
- People are also a barrier. 53% cited senior management issues and 47% cited staff willingness as critical hurdles to adopting new technologies.
- Technology roadmaps reflect growing maturity. Real-time visibility platforms (37%) and logistics partner services (32%) are the most heavily deployed today, with rising interest in NFC/RFID smart labels and serialization to move toward item-level visibility.
- IoT adoption accelerates. Nearly 60% of companies plan to expand IoT monitoring across more lanes and products in the next 18 months in an effort to reduce cold chain integrity failures.